Special Issues

Special Issue Title: Featured Papers in Cardiovascular Medicine 2021

· Print Special Issue Flyer

· Deadline for manuscript submissions: 1 January 2022

Special Issue Editor


Prof. Peter A. McCullough, MD, MPH

Cardiorenal Society of America, Phoenix, AZ, USA

Website | E-Mail

Interests: Cardiorenal medicine; Heart disease; Interventional cardiology;  Kidney disease;  Biomarkers

Special Issue Information

Dear Colleagues,

The arterial pole is one of the most complex parts of the heart both in development and disease. Thus, Cardiovascular Medicine Research plays an increasingly important role in solving societal challenges such as Ventricular arrhythmias, Epidemiology and Lifestyle, in our understanding of molecular biology, and in the advance of medicine. The Special Issue "Feature Papers in Cardiovascular Medicine 2021"  will collect high-quality original research papers and comprehensive reviews on recent advances in cardiovascular disease, vascular disease, heart failure and cardiac disease. The topic of interests include but are not limited to: 

Atherosclerotic cardiovascular disease
Myocardial disease
Valvular disorders
Cardiovascular Imagining
Clinical decision making and real world outcomes

Manuscripts submitted to this Special Issue will be subjected to more stringent selection criteria to ensure the privileged position of accepted contributions. Those that fail to pass this selection will be considered for publication in RCM as regular contributions.

Prof. Dr. Peter A. McCullough, MD, MPH



Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.


Cardiovascular disease; Cardiovascular Imagining; Biomarkers; Genetics; Diagnostic testing; Clinical decision; Puality and outcomes

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
Cardionephrology and cardiorenal disease in Italy: state of the art
Luca Di Lullo, Antonio Bellasi, Vincenzo Barbera, Claudio Ronco
Reviews in Cardiovascular Medicine    2021, 22 (3): 563-572.   DOI: 10.31083/j.rcm2203068
Abstract98)   HTML13)    PDF(pc) (810KB)(150)       Save
The interactions and feedback mechanisms involved in heart and renal failure are more complex than previously thought and are grouped under the term "cardio-renal axis". In the last decades, it has always been emphasized that renal dysfunction in patients with heart failure can be attributed exclusively to low renal plasma flow resulting from reduced cardiac output. In the last two decades cardiorenal syndrome has been established to set complex and close interactions between heart and kidney. Cardiologists and nephrologist should interact in their daily clinical practice to provide better patients' management. In this review, we will point out main features of cardiorenal axis and cardiorenal syndrome to shift into specific sets of management in Italy starting by Guyton's hypothesis till present days.
Related Articles | Metrics
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease
Raffaele Galiero, Alfredo Caturano, Erica Vetrano, Arturo Cesaro, Luca Rinaldi, Teresa Salvatore, Raffaele Marfella, Celestino Sardu, Elisabetta Moscarella, Felice Gragnano, Paolo Calabrò, Ferdinando Carlo Sasso
Reviews in Cardiovascular Medicine    2021, 22 (3): 755-768.   DOI: 10.31083/j.rcm2203082
Abstract97)   HTML16)    PDF(pc) (553KB)(171)       Save
Evidence suggests a close connection between Nonalcoholic Fatty Liver Disease (NAFLD) and increased cardiovascular (CV) risk. Several cross-sectional studies report that NAFLD is related to preclinical atherosclerotic damage, and to coronary, cerebral and peripheral vascular events. Similar results have been showed by prospective studies and also by meta-analyzes on observational studies. The pathophysiological mechanisms of NAFLD are related to insulin resistance, which causes a dysfunction in adipokine production, especially adiponectin, from adipose tissue. A proinflammatory state and an increase in oxidative stress, due to increased reacting oxygen species (ROS) formation with consequent oxidation of free fatty acids and increased de novo lipogenesis with accumulation of triglycerides, are observed. These mechanisms may have an impact on atherosclerotic plaque formation and progression, and they can lead to increased cardiovascular risk in subjects with NAFLD. This review extensively discusses and comments current and developing NAFLD therapies and their possible impact on cardiovascular outcome.
Related Articles | Metrics
Clinical outcomes in patients with heart failure with and without cirrhosis: an analysis from the national inpatient sample
Ali Yazdanyar, Muhammad Haisum Maqsood, Jerald Pelayo, Julien Sanon, Eduardo Quintero, Kevin Bryan Lo, Roy O. Mathew, Janani Rangaswami
Reviews in Cardiovascular Medicine    2021, 22 (3): 925-929.   DOI: 10.31083/j.rcm2203100
Abstract109)   HTML11)    PDF(pc) (104KB)(92)       Save
Outcomes of heart failure (HF) hospitalization are driven by the presence or absence of comorbid conditions. Cirrhosis is associated with worse outcomes in patients with HF, and both HF and cirrhosis are associated with worse renal outcomes. Using a nationally representative sample we describe inpatient outcomes of all-cause mortality and length of stay (LOS) among patients with and without cirrhosis hospitalized for decompensated with HF. We conducted a cross sectional analysis using Nationwide Inpatient Sample (2010–2014) data including patients hospitalized for decompensated HF, with or without cirrhosis. We calculated the adjusted odds of all-cause mortality, acute kidney injury (AKI), and target LOS after adjusting for potential confounders. Out of the 2,487,445 hospitalized for decompensated HF 39,950 had cirrhosis of which majority (75.1%) were non-alcoholic cirrhosis. Patients with comorbid cirrhosis were more likely to die (OR, 1.26; 95% CI, 1.11 to 1.43) and develop AKI (OR, 1.26; 95% CI, 1.16 to 1.36) as compared to those without cirrhosis. Underlying CKD was associated with a greater odds of AKI (OR, 4.99; 95% CI, 4.90 to 5.08), and the presence of cirrhosis amplified this risk (OR, 6.03; 95% CI, 5.59 to 6.51). There was approximately a 40% decrease in the relative odds of lower HF hospitalization length of stay among those with both CKD and cirrhosis, relative to those without either comorbidities. Cirrhosis in patients with hospitalizations for decompensated HF is associated with higher odds of mortality, decreased likelihood of discharge by the targeted LOS, and AKI. Among patients with HF the presence of cirrhosis increases the risk of AKI, which in turn is associated with poor clinical outcomes.
Supplementary Material | Related Articles | Metrics

Current Issue

  • Volume 22, Issue 3